Frank Bedu-Addo - 28 Feb 2024 Form 4 Insider Report for PDS Biotechnology Corp (PDSB)

Role
President/CEO, Director
Signature
/s/ Spencer Brown, Attorney-in-Fact
Issuer symbol
PDSB
Transactions as of
28 Feb 2024
Net transactions value
$0
Form type
4
Filing time
25 Jul 2025, 18:12:55 UTC
Previous filing
06 Jan 2023
Next filing
03 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
BEDU-ADDO FRANK President/CEO, Director C/O PDS BIOTECHNOLOGY CORPORATION, 303A COLLEGE ROAD EAST, PRINCETON /s/ Spencer Brown, Attorney-in-Fact 25 Jul 2025 0001770756

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PDSB Employee Stock Option (Right to Buy) Award $0 +300,000 $0.000000 300,000 28 Feb 2024 Common Stock 300,000 $5.87 Direct F1
transaction PDSB Employee Stock Option (Right to Buy) Award $0 +150,000 $0.000000 150,000 12 Jun 2025 Common Stock 150,000 $1.79 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on February 28,2025, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.
F2 The option will vest over four years, as follows: 25% of the shares underlying the option will vest and become exercisable on June 12, 2026, with the remaining 75% vesting in 36 equal monthly installments thereafter, subject to the Reporting Person's continued service to the Issuer through each vesting date.